Document Detail

Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease.
MedLine Citation:
PMID:  18343648     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Dyspnea and functional limitation in interstitial lung diseases (ILD) are not always adequately explained by the degree of compromise in pulmonary function alone. Pulmonary hypertension (PH) is felt to be a major contributor to morbidity and mortality in these patients. It is not clear whether treatment with newer vaso-active agents benefits patients with PH in the setting of moderate or severe ILD.
METHODS: Medical records of patients followed at our institution between July 2001 and June 2005 were reviewed to identify patients with moderate or severe fibrotic ILD and PH. Data regarding demographics, hemodynamics, and clinical characteristics at baseline and during follow-up were collected.
RESULTS: We identified 19 patients who met our inclusion criteria and in whom vaso-active therapy [epoprostenol (N=10), bosentan (N=9)] was initiated. Most patients [(15/19(79%)] showed an initial positive response to therapy and improved their 6-min walk distance (6MWD) by >50m (responders) and 12/15 (80%) improved by at least 1 WHO functional class. At 1-year follow-up, 7 of 15 (47%) 'responders' had deteriorated significantly. None of the patients died during 1 year of follow-up.
CONCLUSIONS: Epoprostenol and bosentan produced short-term functional benefit in our patients with PH and moderate or severe restrictive ILD. The generalizability of these results awaits the results of larger, prospective, randomized trials in such patients.
Omar A Minai; D Sahoo; J T Chapman; A C Mehta
Related Documents :
9133938 - Comparison of doppler echocardiography and right heart catheterization to assess pulmon...
526798 - A simplified method of monitoring muco-ciliary transport.
17099198 - Physician practice patterns: chest x-ray ordering for the evaluation of acute cough ill...
21087348 - Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function?
23285208 - A pilot study on collective effects of 22q13.31 deletions on gray matter concentration ...
21779708 - Autoantibody profile and clinical correlation in a group of patients with systemic scle...
Publication Detail:
Type:  Journal Article     Date:  2008-03-17
Journal Detail:
Title:  Respiratory medicine     Volume:  102     ISSN:  0954-6111     ISO Abbreviation:  Respir Med     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-06-13     Completed Date:  2008-11-03     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  8908438     Medline TA:  Respir Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  1015-20     Citation Subset:  IM    
Department of Pulmonary, Allergy, and Critical Care Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use
Epoprostenol / therapeutic use
Exercise Tolerance / physiology*
Hypertension, Pulmonary / drug therapy*
Lung Diseases, Interstitial / drug therapy*
Middle Aged
Retrospective Studies
Sulfonamides / therapeutic use
Treatment Outcome
Vasodilator Agents / therapeutic use*
Walking / physiology*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Sulfonamides; 0/Vasodilator Agents; 35121-78-9/Epoprostenol; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Variation in severity and type of sleep-disordered breathing throughout 4 nights in patients with he...
Next Document:  Time to desaturation in the 6-min walking distance test predicts 24-hour oximetry in COPD patients w...